One study demonstrated that the ATR inhibitor AZD6738 induces a synthetic lethal phenotype in ATM‐deficient, but not ATM‐proficient, gastric cancer cells, and in vivo tumor growth of ATM‐deficient gastric cell xenografts was effectively controlled by treatment with AZD6738 compared with control (Min et al., 2017). This evidence concerns the gene ATM and gastric cancer.